Tumor-Induced Osteomalacia in Patients With Malignancy: A Meta-analysis and Systematic Review of Case Reports
Authors' conclusion
We report for the first time a detailed description of the clinical and biological characteristics of malignant TIO. In this context, FGF23 blood measurement would be of value for the diagnostic workup, prognostication, and follow-up of patients.
Study context
- Population
- Patients with malignancy and tumor-induced osteomalacia (hypophosphatemia, malignant tumor-induced osteomalacia (TIO) and FGF23 blood levels reported)
- Participants
- 34 patients32 studies
- Outcome
- Clinical and biological characteristics of malignant TIO
Methodological detailsstrict inclusion criteria, methodological quality grading
- Strict inclusion criteria
- Methodological quality grading
Pooled result
As reported in the abstract
- Most reported tumor: prostate adenocarcinoma
- n = 9
- Metastatic disease
- 25 of 34 patients
- Poor clinical outcome
- 15 of 28 patients
- Median blood phosphate
- 0.40 mmol/L
- Median cFGF23
- 788.5 RU/mL
- Increased alkaline phosphatase
- 20 of 22 patients
Further pooled results
| Outcome | Values |
|---|---|
| cFGF23 by clinical outcome | Poor clinical outcome 1685 RU/mL · Other patients 357.5 RU/mL |
| cFGF23 by tumor type | Prostate cancer 429.4 RU/mL · Other malignancies 1007.5 RU/mL |
cFGF23 by clinical outcome
- cFGF23 significantly higher with poor clinical outcome
cFGF23 by tumor type
- cFGF23 significantly lower in prostate cancer
Original publication
Tumor-Induced Osteomalacia in Patients With Malignancy: A Meta-analysis and Systematic Review of Case Reports. J Clin Endocrinol Metab. Published 26 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →